TMO — Thermo Fisher Scientific Inc
NYSE · Life Sciences Tools & Services · Life Sciences Tools & Services
- Latest Close
- $466.7
- 30-Day Move
- -18.4%
- Market Cap
- $182.3B
- Shares Outstanding
- 371,480,000
- P/E Ratio
- 27.3
- P/B Ratio
- 4.08
Analyst consensus: Buy · 35 analysts
Thermo Fisher Scientific Inc
A read-only Alphactor snapshot forThermo Fisher Scientific Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$466.7
30-Day Move
-18.4%
Market Cap
$182.3B
Shares Outstanding
371,480,000
P/E Ratio
27.3
P/B Ratio
4.08
$466.70
-18.4%last 90 delayed daily bars
90D High
$643.99
90D Low
$455.60
Avg Volume
2,193,936
Gross margin is running at 41.1%, which gives a quick read on operating quality before you open the full model.
Net margin is 15.0%, useful for comparing TMO against peers in Life Sciences Tools & Services.
TMO is down 18.4% over the last 30 trading days shown on this page.
Latest operating income is $2.3B, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$285.69
Rule of 40
18.0%
Latest Close
$466.7
30-Day Move
-18.4%
Market Cap
$182.3B
Shares Outstanding
371,480,000
P/E Ratio
27.3
P/B Ratio
4.08
ROE
12.6%
ROA
6.1%
Gross Margin
41.1%
Operating Margin
17.4%
Net Margin
15.0%
Debt / Equity
0.74
Current Ratio
1.89
Dividend Yield
38.3%
Latest Revenue
$12.2B
Revenue
$12.2B
Gross Profit
$5.0B
Operating Income
$2.3B
Net Income
$2.0B
Gross Margin
4109.0%
Net Margin
1503.0%
Current Ratio
1.89
Debt / Equity
0.74
Fair Value
$285.69
Upside / Downside
-38.8%
Signal
Overvalued
Implied Growth
10.1%
DCF
$194.18
EPV
$142.67
EV/Rev
$520.22
Growth Assumption
-0.3%
Discount Rate
7.7%
Terminal Growth
2.0%
Base FCF
$6.3B
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Altman Z
3.47
Safe
Piotroski
5
Moderate (4-6)
Cash Conversion
1.17x
Rule of 40
18.0%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $44.9B | $8.5B | $7.0B | $6.9B |
| 2023-12-31 | $42.9B | $7.3B | $6.0B | $6.9B |
| 2024-12-31 | $42.9B | $7.7B | $6.3B | $7.3B |
| 2025-12-31 | $44.6B | $8.1B | $6.7B | $6.3B |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 11,807,649 | 0.03% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 9,474,604 | 0.03% | 2025-12-31 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 4,781,351 | 0.01% | 2026-02-28 |
| iShares Trust-iShares Core S&P 500 ETF | 4,789,403 | 0.01% | 2026-02-28 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 4,354,066 | 0.01% | 2026-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Value Index Fund | 3,457,523 | 0.01% | 2025-12-31 |
| SELECT SECTOR SPDR TRT-State Street Health Care Select Sector SPDR ETF | 2,746,033 | 0.01% | 2026-03-31 |
| VANGUARD INSTITUTIONAL INDEX FUNDS-Vanguard Institutional Index Fund | 2,156,252 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Two Sigma Advisers
Filed 2025-11-14
--
--
Vanguard Group
Filed 2026-01-29
$19.8B
+0.9%
BlackRock
Filed 2024-05-10
$16.8B
--
FMR LLC (Fidelity)
Filed 2026-02-17
$5.7B
+29.0%
Geode Capital Management
Filed 2026-02-09
$4.7B
+0.3%
Capital Research Global Investors
Filed 2025-05-12
$3.8B
--
4.2
Consensus
Buy—
—
—
35
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.